Ribozyme mediated down-regulation of thrombospondin receptor CD36 inhibits the growth of the human osteosarcoma cell line

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 371-374

  Yamazaki, Hitoshi ^a   Handa, Akiyoshi ^a   Nishi, Masatake ^a   Tokunaga, Tetsuji ^a   Tomisawa, Masashi ^a   Hatanaka, Hiroyuki ^a   Abe, Yoshiyuki ^b   Kijima, Hiroshi ^a   Ueyama, Yoshito ^a   Nakamura, Masato ^a  

^a TOKAI UNIVERSITY   (Japan)

^b Kanagawa National Hospital   (Japan)

Author keywords

CD36; Osteosarcoma; Ribozyme; Thrombospondin

Indexed keywords

CD36 ANTIGEN; LEUKOCYTE ANTIGEN; MESSENGER RNA; RIBOZYME;

ARTICLE; BONE TUMOR; CELL DIVISION; CONFORMATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KINETICS; METABOLISM; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; TUMOR CELL LINE;

ANTIGENS, CD; ANTIGENS, CD36; BASE SEQUENCE; BONE NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; NUCLEIC ACID CONFORMATION; OSTEOSARCOMA; RNA, CATALYTIC; RNA, MESSENGER;

EID: 3242792731     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.371     Document Type: Article

References (16)

1. Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandona NN and Jamieson GA: Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood 80: 1105-1115, 1992.
2. Dawson DW, Pearce SA, Zhong R, Silverstein R, Frazier W and Bouck NP: CD36 mediates the in vitro inhibitory effects of thrombospondin I on endothelial cells. J Cell Biol 138: 707-717, 1997. (Pubitemid 27349849)
3. Clezardin P, Frappart L, Clerget M, Pechoux C and Delmas PD: Expression of thrombospondin(TSP1) and its receplors(CD36, CD51) in normal, hyperplastic and neoplastic human breast. Cancer Res 53: 1-10, 1993.
4. Pechoux C, Clezardin P, Dante R, Serre CM, Clerget M and Bertin N: Localization of thrombospondin. CD36 and CD51 during prenatal development of the human mammary gland. Differentiation 57: 133-141, 1994. (Pubitemid 24211108)
5. Gehron RP, Young MF, Fisher LW and McClain TD: Thrombospondin is an osteoblast-derived component of mineralized extracellular matrix. J Cell Biol 108:719-727, 1989. (Pubitemid 19065867)
6. Tsuchida T, Kijima H, Tokunaga T, Oshika Y, Hatanaka H, Fukushima Y, Abe Y, Kawai K, Yoshida Y, Miura S, Yamazaki H, Tamaoki N, Ueyama Y and Nakamura M: Expression of the thrombospondin 1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer. Int J Oncol 14: 47-51, 1999.
7. Tokunaga T, Nakamura M, Oshika Y, Tsuchida T, Kazuno M, Fukushima Y, Kawai K, Abe Y, Kijima H, Yamazaki H, Tamaoki N and Ueyama Y: Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch 433: 415-418, 1998. (Pubitemid 28522029)
8. Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M and Scanlon KJ: Therapeutic applications of ribozymes. Pharmacol Ther 68: 247-267, 1995. (Pubitemid 26094034)
9. Scanlon KJ, Ohta Y, Ishida H, Kijima H, Ohkawa T, Kaminski A, Tsai J, Horng G and Kashani-Sabet M: Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9: 1288-1296, 1995.
10. Noonberg SB, Scott GK, Garovoy MR, Benz CC and Hunt CA: In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation. Nucleic Acids Res 22: 2830-2836, 1994. (Pubitemid 24238118)
11. Tokunaga T, Abe Y, Tsuchida T, Hatanaka H, Oshika Y, Tomisawa M, Yoshimura M, Ohnishi Y, Kijima H, Yamazaki H, Ueyama Y and Nakamura M: Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int J Oncol 21: 1027-1032, 2002.
12. Kamochi J, Tokunaga T, Morino F, Nagata J, Tomii Y, Abe Y, Hatanaka H, Kijima H, Yamazaki H, Watanabe N, Matsuzaki S, Ueyama Y and Nakamura M: Ribozyme mediated suppression of vascular endothelial growth factor gene expression enhances matrix metalloproteinase 1 expression in a human hepatocellular carcinoma cell line. Int J Oncol 21: 81-84, 2002.
13. Oshika Y, Nakamura M, Tokunaga T, Ohnishi Y, Abe Y, Tsuchida T, Tomii Y, Kijima H, Yamazaki H, Ozeki Y, Tamaoki N and Ueyama Y: Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur J Cancer 36: 2390-2396, 2000.
14. Tokunaga T, Tsuchida T, Kijima H, Okamoto K, Oshika Y, Sawa N, Ohnishi Y, Yamazaki H, Miura S, Ueyama Y and Nakamura M: Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br J Cancer 83: 833-839, 2000.
15. Morino F, Tokunaga T, Tsuchida T, Handa A, Nagata J, Tomii Y, Kijima H, Yamazaki H, Watanabe N, Matsuzaki S, Ueyama Y and Nakamura M: Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line. Int J Oncol 17: 495-499, 2000.
16. Silva ID, Salicioni AM, Russo IH, Higgy NA, Gebrim LH and Russo J: Tamoxifen down-regulates CD36 messenger RNA levels in normal and neoplastic human breast tissues. Cancer Res 57: 378-381, 1997. (Pubitemid 27081649)